Forest Labs agreed to acquire Clinical Data for $30/share cash plus contingent consideration of up to $6/share tied to Viibryd commercial milestones, total ~$1.2B fully diluted. Viibryd had been FDA-approved for MDD on January 21, 2011.
Did it work? Outcome assessment
Strategic verdict
Partially Achieved
Financial impact
Dilutive
Pipeline outcome
Assets Advanced
Assessment window: 5yr post-close.
Key facts
AnnouncedFeb 22, 2011
ClosedApr 01, 2011
Deal value$1.2B
Deal typeAcquisition/Merger
Therapeutic areaMajor Depressive Disorder (MDD)
IndicationsMajor Depressive Disorder (MDD)
Key assetsViibryd (vilazodone HCl)
MechanismSSRI plus 5-HT1A receptor partial agonist